Australia's lung cancer screen turns one — and the gaps are showing

What just happened

Australia now has a lung cancer screening programme. That sentence alone is worth reading slowly — because for the longest time, it didn’t.

Lung cancer is the most common cause of cancer death in Australia. It kills more Australians than breast, prostate, and bowel cancer combined. And until July 2025, there was no funded, systematic programme to find it early in the people most at risk. The National Lung Cancer Screening Program (NLCSP) changed that — offering free low-dose CT scans as a Medicare-rebated benefit, for the first time in this country’s history.

In its first year, the programme screened approximately 50,000 high-risk individuals. The eligibility criteria are specific: aged 50 to 70, with a smoking history of at least 30 pack-years — the equivalent of one pack of twenty cigarettes per day for thirty years — who currently smoke or have quit within the last ten years. The process begins with a GP referral. No symptoms required — and for the vast majority of people who will be diagnosed with lung cancer, that is precisely the point. Lung cancer caught at an early stage is associated with five-year survival rates approaching 70%, compared with under 5% when diagnosed at advanced disease.

That gap — 70% versus 5% — is the entire clinical argument for the programme’s existence. It is also why a 2026 paper in the Medical Journal of Australia, led by Fraser Brims and colleagues, sounds an urgent and specific note: the screening programme can only deliver on what it promises if the clinical infrastructure to act on what it finds is adequately resourced. Screening, the paper argues, is not the end of the equation — it is the beginning.

---

The both-and

The NLCSP is a genuine advance. The system that catches what it detects is not yet built to the scale required. Both are true.

The Lung Foundation Australia has been advocating for a national lung cancer screening programme for years. The July 2025 launch represented a policy achievement built on evidence from the US National Lung Screening Trial, European trial data, and Australian epidemiological modelling. The eligible population — Australians aged 50–70 with a heavy smoking history — is the cohort where the detection benefit is most clearly established.

The Brims team’s MJA paper identifies what happens downstream as the critical variable. Detecting an abnormality on a low-dose CT scan opens a clinical pathway: characterising the nodule, deciding on surveillance versus further investigation, managing patient anxiety during what can be a prolonged period of uncertainty, and potentially referring to a thoracic multidisciplinary team. That pathway requires workforce — radiologists, respiratory physicians, thoracic surgeons, specialist nurses — and it requires them in the places where the programme is reaching people. As the Institute for Respiratory Health noted in February 2026, the multidisciplinary lung cancer workforce across Australia, particularly in regional and remote areas, is not evenly distributed to match the programme’s geographic reach.

The equity dimension sharpens that concern further. Aboriginal and Torres Strait Islander peoples experience lung cancer at approximately twice the rate of non-Indigenous Australians, often at younger ages and with more advanced disease at diagnosis. Mobile CT services are planned for some rural and remote communities — NSW from November 2026 — but mobile imaging addresses only one node of what is a complex pathway from screen to treatment. Historically, the communities carrying the highest burden of disease are the communities with the fewest specialist resources to respond to what screening finds.

There is also the question of stigma. Lung cancer carries a heavy stigma — the association with smoking is used, in clinical and social settings, in ways that actively suppress help-seeking. A person who quit fifteen years ago may still be reluctant to raise their smoking history. A person who continues to smoke may anticipate judgement rather than practical assistance. The NLCSP depends on GPs creating consultations where the smoking history can be disclosed and assessed without that weight landing first.

---

2 cents

If you are aged 50 to 70, have a 30 pack-year smoking history, and currently smoke or have quit within the last ten years — this programme exists for you. The scan is free with a GP referral. If you have not had that conversation yet, it is worth starting it.

If you quit more than ten years ago, you are not currently eligible under the NLCSP criteria — that reflects where the evidence for screening benefit is most concentrated. It does not mean your lungs are not worth monitoring; your GP can advise on your individual risk based on your full history.

The programme has limits. Those limits are the next policy task. They do not erase the value of what has been built.

This is general information. Eligibility and appropriate clinical management are determined in the consulting room with your GP and your individual history.

---

Verdict

Verdict: yes — worth knowing about.

Australia’s lung cancer screening programme is real, it is funded, and in its first year it reached 50,000 people. The survival difference between early and advanced disease detection is clinically profound and well-established. The programme’s systemic risks — workforce gaps, no national quality registry, inequities for rural and Indigenous communities, the stigma barrier — are named in the peer-reviewed record and are the legitimate focus for the next phase of investment. The promise is genuine. The work to keep it is ongoing.

---

Sources cited

1. National Lung Cancer Screening Program — Department of Health and Aged Care
2. National Lung Cancer Screening Program — Lung Foundation Australia
3. Brims et al. 2026 — National Screening, National Responsibility (Medical Journal of Australia)
4. Australia’s lung cancer screening promise at risk — Institute for Respiratory Health
5. National Lung Cancer Screening Program — Cancer Australia